Concepedia

Andreas Brueckner

AB

Statistics

Publications

7

Citations

823

H-Index

7

Active since

2010

Affiliations

Novartis (Switzerland)(Current)

Bayer (Germany)

Inserm

Uppsala Monitoring Centre

Eli Lilly (United States)

Andreas Brueckner is an author at Novartis (Switzerland) specializing in pharmacology, pharmacy, and pharmacovigilance.

ORCID

Publications per year

2010–2024

7

Publications

7

The REporting of A Disproportionality Analysis for DrUg Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Explanation and Elaboration

Michele Fusaroli, Francesco Salvo, Bernard Bégaud et al. · Drug Safety · 2024 · 273 citations · Full text

, , +15

The Reporting of a Disproportionality Analysis for Drug Safety Signal Detection Using Individual Case Safety Reports in PharmacoVigilance (READUS-PV): Development and Statement

Michele Fusaroli, Francesco Salvo, Bernard Bégaud et al. · Drug Safety · 2024 · 183 citations · Full text

, , +16

Good Signal Detection Practices: Evidence from IMI PROTECT

A Wisniewski, Andrew Bate, Cédric Bousquet et al. · Drug Safety · 2016 · 144 citations · Full text

, , +17

Thin wafer-level camera lenses inspired by insect compound eyes

Andreas Brueckner, Jacques Duparré, Robert Leitel et al. · Optics Express · 2010 · 141 citations · Full text

, , +10

Sorafenib tolerability in elderly patients with advanced renal cell carcinoma: results from a large pooled analysis

Giuseppe Procopio, Joaquim Bellmunt, Janice P. Dutcher et al. · British Journal of Cancer · 2013 · 50 citations · Full text

, , +16

1–5 of 7